MANAGING FIBROSIS RISK
Utilizing RNA gene signatures to more accurately risk stratify outcome from fibrosis in a transplant patient.
The challenge of risk assessment.
Fibrosis often develops following acute organ rejection, during which antibodies may target the transplanted kidney. Currently, histological analysis from a biopsy remains the primary method for stratifying fibrosis risk; however, effectively managing fibrosis has long posed a significant challenge for transplant clinicians.
More information, more appropriate treatments.
Protega™ leverages an RNA gene signature to more accurately stratify the risk of fibrosis-related outcomes in transplant patients. Doing so may give clinicians additional information to help them select appropriate treatments that will delay or mitigate progressive fibrosis.
This product is currently being validated.
Contact us to learn more.
